Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável

Abstract

INTRODUCTION: Irritable Bowel Syndrome (IBS) is one of the most common functional disorders of the gastrointestinal system, and differences in the composition of the luminal microbiota of patients with IBS have been observed in most of the bacterial taxonomic levels. Therefore, the use of probiotics is considered an alternative and supporting therapy in the treatment. METHODOLOGY: It is a qualitative study of narrative review, in which PubMed, Google Scholar, Cochrane Library, EMBASE, MedLine, Scopus and Clinicaltrial.gov databases were used. The descriptors found in DeCS and Emtree were used: “therapy”, “irritable bowel syndrome” and “probiotics”, and 24 articles were selected. RESULTS: Most of the results are promising, but it is not possible to define precisely which probiotic or which mixture of probiotics is effective, and which dose and duration of treatment. DISCUSSION: Several studies point out the beneficial effects in the use of the combination of probiotics in patients with IBS, even though the mechanism of action of these microorganisms in the relief of these symptoms remains uncertain. CONCLUSION: It is necessary to conduct more randomized clinical trials in order to determine which bacterial strains, concentrations and duration of treatment is more effective in addressing patients.